



Biotech Capital (BTC) - ASX Announcement

14 February 2017

Biotech Capital Completes Successful Capital Raising to Fund Growth

- \$1.79 million placement now complete
- Share Purchase Plan will enable participation by existing shareholders

Biotech Capital Limited (ASX:BTC) ("BTC") is pleased to announce the completion of a \$1.79 million Private Placement. An associated Share Purchase Plan (SPP) will also offer existing eligible shareholders the opportunity to increase their shareholding. The Placement was made to institutional, sophisticated and professional investors. Of the total 16,289,670 shares issued under the placement Directors intend to take up a total of 2,772,981 shares, the issue of which will be subject to shareholder approval at the next Annual General Meeting. The directors allocation was scaled back from original requests due to over-subscription of the placement.

Proceeds from the private placement and the SPP will be used to build greater capabilities for the group in regulatory, quality and clinical services, establish a Melbourne office for Biointelect, promote the group's services to overseas clients and proceed with a number of strategic appointments in coming months. Through its wholly-owned subsidiary, BioImpact, the group is actively pursuing opportunities to in-license intellectual property rights to novel drugs and medical devices.

The issue price of the Placement is 11c per share which represents a 8.33% discount to BTC's last closing price of 12c on 10 February 2017 and an 8.33% discount to BTC's 10 day VWAP. All new Placement shares will be issued and will rank equally with the existing shares.

Chairman Dr. Richard Treagus, said "We are delighted with the level of support we received in this recent placement. The BTC group is executing on its growth plans and with these additional funds the Company is now well placed to expand its service offering, attract the best industry talent and to actively pursue in-licensing and acquisition opportunities from local and international third parties."

Share Purchase Plan

BTC is pleased to announce a share purchase plan, which is not underwritten. The SPP will allow each eligible shareholder, holding shares on the record date of 13 February 2017, the opportunity to apply for up to \$15,000 of fully paid ordinary shares in BTC.

The issue price of shares under the SPP will also be 11c.

The Directors may, in their absolute discretion, decide to issue to any person fewer shares than that which such person applied for under the SPP. This may be by way of a scale back mechanism.

Details of the offer will be released to ASX today and mailed to eligible shareholders by 16 February 2017.

For further information contact:

Dr. Richard Treagus – Executive Chairman
Phone +61 417 520 509



About Biotech Capital

Biotech Capital Ltd (“BTC”) is a listed investment fund currently actively seeking new investment opportunities in entities operating in the biotechnology / life-science sectors. As a registered Pooled Development Fund (PDF), investors are generally exempt from tax on capital gains and income. BTC is listed on the Australian Stock Exchange (Code: BTC). Additional information can be found at www.biotechcapital.com.au

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such Statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Biotech Capital to be materially different from the statements in this announcement.